Expression of Alpha-Enolase (ENO1), Myc Promoter-Binding Protein-1 (MBP-1) and Matrix Metalloproteinases (MMP-2 and MMP-9) Reflect the Nature and Aggressiveness of Breast Tumors by Cancemi, P. et al.
 International Journal of 
Molecular Sciences
Article
Expression of Alpha-Enolase (ENO1), Myc
Promoter-Binding Protein-1 (MBP-1) and Matrix
Metalloproteinases (MMP-2 and MMP-9) Reflect the
Nature and Aggressiveness of Breast Tumors
Patrizia Cancemi 1,2,* , Miriam Buttacavoli 1 , Elena Roz 3 and Salvatore Feo 1,2
1 Department of Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF),
University of Palermo, 90128 Palermo, Italy
2 Centro di OncoBiologia Sperimentale (COBS), 90145 Palermo, Italy
3 La Maddalena Hospital III Level Oncological Department, 90145 Palermo, Italy
* Correspondence: patrizia.cancemi@unipa.it
Received: 1 July 2019; Accepted: 7 August 2019; Published: 14 August 2019


Abstract: Breast cancer is a complex and heterogeneous disease: Several molecular alterations
cause cell proliferation and the acquisition of an invasive phenotype. Extracellular matrix (ECM)
is considered essential for sustaining tumor growth and matrix metalloproteinases (MMPs) have
been identified as drivers of many aspects of the tumor phenotype. Mounting evidence indicates
that both α-enolase (ENO1) and Myc promoter-binding protein-1 (MBP-1) also played pivotal roles
in tumorigenesis, although as antagonists. ENO1 is involved in cell growth, hypoxia tolerance and
autoimmune activities besides its major role in the glycolysis pathway. On the contrary, MBP-1, an
alternative product of ENO1, suppresses cell proliferation and the invasive ability of cancer cells.
Since an important task in personalized medicine is to discriminate a different subtype of patients
with different clinical outcomes including chances of recurrence and metastasis, we investigated the
functional relationship between ENO1/MBP-1 expression and MMP-2 and MMP-9 activity levels
in both tissues and sera of breast cancer patients. We focused on the clinical relevance of ENO1
and MMPs (MMP-2 and MMP-9) overexpression in breast cancer tissues: The association between
the higher ENO1, MMP-2 and MMP-9 expression with a worse prognosis suggest that the elevated
ENO1 and MMPs expression are promising biomarkers for breast cancer. A relationship seems to
exist between MBP-1 expression and the decrease in the activity levels of MMP-9 in cancer tissues
and MMP-2 in sera. Moreover, the sera of breast cancer patients grouped for MBP-1 expression
differentially induced, in vitro, cell proliferation and migration. Our findings support the hypothesis
of patient’s stratification based on ENO1, MBP-1 and MMPs expression. Elucidating the molecular
pathways through which MBP-1 influences MMPs expression and breast cancer regression can lead
to the discovery of new management strategies.
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1. Introduction
Normal cells progressively evolve towards a neoplastic state through a multistep process, during
which they acquire new traits or capability, defined as “cancer hallmarks”, including: Deregulation
of cell growth and death, sustained angiogenesis, tissue invasion and metastasis. All these aspects
contribute to the development of a tumorigenic and ultimately malignant, cell phenotype. Underlying
these hallmarks are genome instability, tumor-promoting inflammation, reprogramming of energy
metabolism and evading immune destruction [1]. Moreover, tumors represent a complex ecosystem,
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in which normal cells can contribute to the acquisition of hallmark traits by creating the “tumor
microenvironment” [2]. New molecular insights into cancer progression pointed also to extracellular
matrix (ECM) turnover, which results quantitatively and qualitatively deregulated [3–5]. Remarkably,
increased expression and/or activity of proteolytic enzymes, especially the matrix metalloproteinases
(MMPs), are frequently associated with poor prognosis in cancer patients [6]. MMP-mediated ECM
remodeling can promote the release of matrix-associated growth factors, or cytokines, modulating
the activity or bioavailability of signaling molecules. In addition MMP activities also result in the
generation of matrix fragments displaying novel biological activity [7]. The c-MYC proto-oncogene is
considered a driver oncogene, being to be involved in 20% of all human cancers. More recently, it is
suggested that c-MYC could regulate as many as 15% of genes in different genomes, with more than
3.000 genes in human [8]. The pivotal role of c-MYC in regulating cell proliferation and cell death
is consistent with the observations that its expression is tightly controlled by several mechanisms,
including changes in transcription initiation and transcript elongation, as well as stability, turnover
and translational state of mRNA [9]. The Myc promoter-binding protein-1 (MBP-1), has been identified
as a protein of 37-38 kDa that binds the human c-MYC P2 promoter and negatively regulates c-MYC
transcription by preventing the formation of the transcription initiation complex [8]. MBP-1 is a short
form of the 48 kDa alpha-enolase protein, lacking the first 96 amino acid [9].
ENO1, a key glycolytic enzyme, contributes to the known “Warburg effect” that is the high
glycolytic rate of cancer cells, even in presence of oxygen, and necessary to support the biosynthetic
requirements of uncontrolled proliferation [10]. Moreover, the microenvironment acidification and
other metabolic crosstalk alter the tumor-stroma interface, allowing the enhanced invasiveness of
tumors [11,12]. It is evident that the cooperation of multiple factors rather than the involvement of a
single factor is needed to induce malignancy. This hypothesis is widely considered to be more likely to
define therapeutic avenues directed at multiple molecular targets for more effective cancer treatment.
MBP-1 expression has been correlated with the inhibition of proliferation, migration, invasion and
epithelial–mesenchymal transition (EMT) [13–15]. On the other hand, MMP-9 is rapidly induced and
activated in response to c-MYC [16] and it was demonstrated that MBP-1 modulates MMP expression
and inhibits the in vitro angiogenesis [17].
Among tumors, breast cancer is a highly heterogeneous disease, both at histological and molecular
level. Patients diagnosed at the same stage of the disease and who received the same treatment, often
show very different clinical responses and survival periods [18]. In this scenario, the main concern is to
identify clinically homogeneous patient subgroups to evaluate the risk-benefit balance of treatment,
maximizing the therapeutic efficacy, but avoiding to a significant number of subjects to be treated
without receiving any benefit.
Advances in genomics/proteomics technologies provide unprecedented opportunities for rapid
advancement in translational medicine [19,20].
Here, we investigated the functional relationship, in a cohort of breast cancer patients, between
ENO1/MBP-1 expression and MMP-2 and MMP-9 activity levels in both tissues and sera. We also
analyzed in vitro the clinical relevance on predicting two important aspects of cancer: Growth and
migration. Our results showed that ENO1, MMP-2 and MMP-9 are overexpressed in breast cancer
tissues compared to the non-tumoral adjacent one, and how their higher expression level is associated
with a worse prognosis. A relationship seems to exist between MBP-1 expression and the decrease of
the activity levels of MMP-9 in tumoral tissues and MMP-2 in sera. Moreover, the sera of breast cancer
patients, grouped for MBP-1 expression, differentially induced in vitro cell proliferation and migration,
suggesting that both MBP-1 and MMPs reflect the nature and aggressiveness of breast tumors and can
be used for patients’ stratification.
These findings support the hypothesis that MBP-1 expression can modify the tumor
microenvironment decreasing the levels of molecules related to cancer progression. Further studies will
be necessary to elucidate the molecular pathways through which MBP-1 influences MMPs expression
and breast cancer regression, in order to translate these information into the clinical practice.
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2. Results
2.1. Overexpression of ENO1 in Breast Cancer Tissues
The expression levels of ENO1 (48 kDa) was evaluated by western blot in a subset of 24 breast
cancer tissues and their paired non-tumoral adjacent tissues. Protein loading was ascertained by actin
beta (ACTB) expression (Figure 1A). All non-tumoral adjacent tissues showed very low expression
of alpha-enolase, whereas its high expression was observed in the paired tumor samples. Statistical
analysis of Western blot data confirmed the presence of significantly higher levels ofENO1 in breast
cancer samples rather than in normal tissues (Figure 1B). The prognostic value of ENO1 mRNA
expression in breast cancer patients using the Kaplan–Meier plotter database was also investigated.
Patients were split into two groups by using the best cut-off of probe expression, and survival was
evaluated as distant metastasis-free survival (DMFS). Results showed that higher ENO1 expressions
were significantly associated with a worse prognosis (highlighted in red, Figure 1C; p = 1.5 × 10−7).
Collectively, these results suggest that ENO1 is overexpressed both at the mRNA and the protein level
in breast cancer tissues, and the upregulated ENO1 mRNA is correlated with a worse prognosis.
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and paired non-tumoral adjacent tissues (NAT); n = 24. (C) Graphic quantification of western blot
results. Each data point is the average of three independent experiments. Error bars represent the
standard deviation and the p value indicates statistical significance. (D) Survival analysis in breast
cancer patients obtained from the Kaplain–Meir plotter database relative to ENO1 mRNA expression.
2.2. Upregulation of MMP-9 and MMP-2 in Breast Cancer Tissues
The proteolytic degradation of the ECM operated by MMPs represent a key aspect of tumor
progression, since ECM is the first barrier against cell invasion. Therefore, in the same subset of
24 patients, the enzymatic activities of MMP-2 and MMP-9 were also evaluated by zymography.
As shown in Figure 2A, the majority of the breast cancer tissues were positive for the lytic activities
corresponding to the latent and activated form of MMP-2 and MMP-9. On the contrary, the non-tumoral
counterparts were generally positive only for the latent form of MMP-2 and MMP-9. Further, lytic
bands of high molecular weight, corresponding to the homodimeric forms of MMP-9 and complexes
of pro-MMP-9/TIMP-1, respectively, also occurred in some patients, as already reported [21,22]. The
densitometric quantification of the activity levels was performed as relative volumes, calculated as
an area X optical density, using ImageJ software. As shown in the graphs (Figure 2B), the activity
levels of pro-MMP-2, MMP-2, pro-MMP-9, and MMP-9 were significantly higher in the tumoral tissues,
as compared to the non-tumoral adjacent tissues. Overexpression of MMP-2 and MMP-9 mRNA
were also correlated with poor outcome as evaluated by distant metastasis free survival (DMFS) in
the Kaplan–Meier plotter database (Figure 2C). Collectively, these results suggest that MMPs are
overexpressed in breast cancer tissues, and the upregulated MMP-9 and MMP-2 mRNAs are correlated
with a worse prognosis.
2.3. MBP-1 Expression in Breast Cancer Tissues
The concomitant expression of ENO1 (48 kDa) and MBP-1 variant (37 kDa) was evaluated in
a cohort of 29 breast cancer tissues. Protein loading was ascertained by ACTB expression. Among
the analyzed patients, 12 were positive for MBP-1 expression while 17 were negative (Figure 3A).
Moreover, in all cases, the expression levels of ENO1 are higher than MBP-1. Western blot analysis
results were also validated by immunohistochemistry by using the monoclonal antibody Eno 19/8
which recognizes an epitope within the aminoacids residues 275-344 [23,24]. As previously reported,
cytoplasmatic staining is due to the ENO1 expression, while nuclear staining depends on the MBP-1
expression. A panel of representative immunohistochemical (IHC) staining images of MBP-1 in normal
mammary and breast cancer tissues (both positive and negative) were shown in Figure 3B. IHC analysis
revealed a strong MBP-1 staining in nuclei of healthy mammary tissues, while in breast cancer tissues
only the selected samples showed the nuclear staining. In all cases, cytoplasmic staining correspond
to ENO1 (48 kDa) expression. According to the western blot and immunohistochemical analyses on
MBP-1 expression, breast tumors were classified as MBP-1−ve and MBP-1+ve.
2.4. MBP-1 Expression is Associated with MMPs Down-Regulation
To verify if the expression of MMPs in breast cancer tissues was different between MBP-1-ve and
MBP-1+ve tumors, zymographic analysis in the two groups of patients was performed (Figure 4A). The
obtained results clearly indicated a significant down regulation of MMP-9 (both the proenzyme and the
active enzyme) in MBP-1+ve tumors (Figure 4B). MMP-2 activity levels were not significantly affected.
Following this, to evaluate if the MMPs activity levels could be also affected in sera samples
of breast patients previously stratified as MBP-1-ve and MBP-1+ve, the zympgraphic analysis on
sera samples collected before surgery was performed. Sera samples (n = 16) of healthy donors
were used as control specimens. In all the analyzed sera, only the enzymatic activity of ProMMP-9
and ProMMP-2 was detected, while no enzymatic activity was detected for the activated forms
(Figure 5A). Densitometric analysis of the lytic bands showed that the activity values of pro-MMP-2
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were significantly higher in MBP-1-ve breast cancer sera compared to MBP-1+ve and healthy sera
(Figure 5B). No statistical differences were found among the three groups for ProMMP-9 activity.Int. J. Mol. Sci. 2019, 20, x 5 of 17 
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Figure 2. MMP-9 and MMP-2 enzymatic activity in normal and breast cancer tissues and prognostic
significance. (A) Gelatin zymography was performed using total lysates from breast tumors (BCT)
and paired non-tumoral adjacent tissues (NAT); n= 24. (B) Densitometric analysis of the gelatinolytic
bands. Each data point is the average of three independent experiments. Error bars represent standard
deviation and p values indicate statistical significance. (C) Survival analysis in breast cancer patients
obtained from Kaplain–Meir plotter database relative to MMP-9 and MMP-2 expression.
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2.5. Contributing Role of MBP-1-ve and MBP-1+ve Breast Cancer Sera in Cell Proliferation and Aggressiveness
To establish if the sera of MBP-1-ve and MBP-1+ve breast tumors were able to affect cell growth
and migration, the MDA-MB-231 cells were used as prototype of highly proliferative and metastatic
tumor model. Cell proliferation was evaluated by MTT assay after 24 h of treatment with 1% sera from
MBP-1-ve or MBP-1+ve breast canc r patients, compared to 1% Foetal Bovin Serum (FBS) treatment.
The treatment with MBP-1+ve breast sera reduced significantly cell proliferation rate, although a high
heterogeneity was recorded with some sera (Figure 6A). The effect of MBP-1-ve and MBP-1+ve breast
sera on MDA-MB-231 cell motility was also evaluated by in vitro wound healing assay. As shown in
Figure 6B, the migratory capability of MDA-MB-231 cells treated with MBP-1-ve sera was considerably
increased compared to the FBS treatment. Interestingly, the enhanced migration induced by MBP-1−ve
sera was diminished in MDA-MB-231 cells treated with MBP-1+ve sera (Figure 6B,C). In summary, the
obtained results suggest that MBP-1+ve tumors are less aggressive than MBP-1-ve tumors.
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(A) Relative cell growth measured by MTT assay. MDA-MB-231 cells were starved for 24 h (0% FBS)
and then treated for 24 h with 1% FBS or 1% of human sera from breast cancer patients, previously
grouped as MBP-1−ve and MBP-1+ve. (B) Wound healing of MDA-MB-231 cells after stimulation with
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MBP-1+ve. Migration at the edge of the scratch was analyzed at 0, 6 and 24 h (magnification, 100×). (C)
Quantification of cell migration was performed measuring the scratch wound, and results are expressed
relative to the closure of 1% FBS treatment.
3. Discussion
Although several efforts have been directed toward understanding the molecular mechanisms
underlying tumorigenesis, the prognosis of different patients is much more difficult to define based on
some molecular/clinical parameters. The demand for novel/personalized therapies is continuously
increasing, therefore it is urgent to find new biomarkers for better classification and prognosis prediction,
as well as the response to therapy.
Here, we provide new evidences about the clinical relevance of ENO1 and MMPs (MMP-2
and MMP-9) overexpression in breast cancer tissues. All non-tumoral breast tissues showed low
expression/activity of both ENO1 and MMP-2 and MMP-9, whereas higher expression/activity was
observed in the paired tumour samples. A clear association between the higher mRNA expression
level of ENO1, MMP-2 and MMP-9 with a worse prognosis was already detected, suggesting that the
elevated ENO1 and MMPs are promising biomarkers for breast cancer.
ENO1 is a glycolytic enzyme and a multifunctional protein that plays a crucial role in a variety of
biological and pathophysiological processes [25]. According to the well-known Warburg effect, cancer
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cells highly express almost all glycolytic enzymes [26], including ENO1, which is upregulated both at
the mRNA and the protein level in several tumors including breast [27]. Aberrant expression of ENO1
has been associated with multiple tumor progression both in vitro [28–31] and in vivo [32–36] and
higher levels of ENO1 has been correlated with poor prognosis [37,38]. This evidence can be partially
explained considering the Warburg effect [30], consisting in the ability to switch the cell metabolism
from predominantly oxidative to glycolysis and the production of lactate, even if the oxygen is plentiful.
Switching to the aerobic glycolysis is a key characteristic of cancer metabolism, being critical for both
tumor cell growth and migration [39]. In fact, the acidification of extracellular milieu providing a
favorable microenvironment for the activation of proteases, e.g., MMPs, induce ECM degradation and
facilitate tumor cells to metastasize [40]. MMPs, originally described as regulators of ECM remodeling
and facilitators of tumor growth, modulate the activity of both inducers and inhibitors of tumorigenesis,
by processing cytokines, angiogenic and growth factors, and their respective receptors, as well as
altering cell adhesion and stimulating epithelial to mesenchymal transition [41,42]. The expression
and activity of MMPs are increased in almost every type of human cancer, including breast cancer, and
correlate with an advanced tumor stage, increased invasion, metastasis, and shortened survival [43,44].
Generally, in tumors, MMPs are deregulated by transcriptional changes rather than genetic alterations
such as amplification or activating mutations. This might be the result of activation of oncogenes
or loss of tumor suppressors. MBP-1, a nuclear short variant of ENO1 [9] acting as a transcriptional
repressor, could represent a good link for MMPs regulation. MBP-1 is an oncosuppressor, negatively
regulating cell proliferation or promoting cancer cell apoptosis when overexpressed in vitro [45–47].
Its tumor-suppressor function depends on the repression of at least three gene targets, namely:
c-MYC, COX2 and ERBB2 [9,48,49]. The MBP-1-mediated repression also depends on the association
with different partners, such as: MIP-2/sedlin [50], histone deacetylase 1 [48,51], the kelch protein
NS1-BP [23], and the intracellular domain of the Notch 1 receptor [52]. Moreover, MBP-1 suppresses,
in vitro, tumor invasion and metastasis in different models of cancer [13,49,53]. In breast cancer, MBP-1
expression inversely correlates with the ErbB2 and Ki67 expression levels and it is a good predictor of
disease-free survival [24].
To our knowledge this is the first study reporting the association of MBP-1 expression and MMPs
activity in clinical breast cancer tissues. In particular, our analysis showed a significant lower activity
of both ProMMP-9 and MMP-9 in MBP-1+ve patients. In fact, MMP-9 is induced under conditions
that require tissue remodeling (including tumor invasion) [54]. A direct link has been established
between MMPs transcriptional regulation by COX-2 [55], HER2 [56] and c-MYC [57,58], therefore we
hypothesize that MBP-1 expression, through the downregulation of its specific targets, can regulate the
tissue levels of MMP-9.
Our analysis showed a relationship between MBP-1 expression and the decrease of ProMMP-2
in breast cancer sera, proving for the first time that MBP-1 tissue expression could influence tumor
aggressiveness by influencing the composition of the microenvironment and/or the mobilization
of factors related to the biological features of the tumor. More interestingly, MBP-1 expression
influences MMPs activity levels in different compartments (ProMMP-9 and MMP-9 in breast tissues
and ProMMP-2 in sera) underlining unique functions for both proteolytic enzymes. We previously
showed the complexity of the interactive networks (partly common and partly exclusive) through which
MMP-2 and MMP-9 drive their functions [59], which also depend on the cell type and environment.
These complex interactive molecular circuits suggest their potential involvement in other important
cellular activities, besides that of remodeling the extracellular matrix.
Because cancer aggressiveness depends also on the ability to induce proliferation and migration
we further examined the effects of sera from MBP-1-ve patients versus MBP-1+ve patients to stimulate
proliferation and migration in the MDA-MB-231 breast cancer cells. The cell proliferation rate and
migration was significantly reduced by using the MBP-1+ve compared to MBP-1-ve breast cancer sera,
although a high heterogeneity was recorded with some sera. The modulation of cell proliferation and
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migration accounts for specific factors that are differentially enriched in each serum, but collectively this
is the first indication that breast tumors MBP-1+ve have a lower proliferative and migratory capacity.
Our results are in agreement with the observation that MBP-1 expression results in the modulation
of MMP-2 expression [60], the inhibition of in vitro angiogenesis and the regression of primary [53]
and metastatic breast tumor growth [13]. Endogenous levels of ENO1 are higher than MBP-1 due
to differences in translational efficiency, translational regulation and posttranslational stability [61].
Although the mechanisms regulating MBP-1/ENO1 ratio are not fully understood, several factors such
as hypoxia [62], Endoplasmic Reticulum stress [63] and glucose concentrations [64] were described to
influence MBP-1 and ENO1 transcription, strongly suggesting that posttranscriptional mechanisms
might play a role in the regulation of MBP-1 expression in breast cancer cells. Accordingly, a molecular
switch of ENO1 translation in favor of MBP-1 translation could convert very aggressive breast cancer
tumors into less aggressive tumors.
4. Materials and Methods
4.1. Patients, Tissue and Sera Samples
A total of 53 patients diagnosed with breast ductal infiltrating carcinomas with histological grading
G2/G3 and without clinically apparent metastases were involved in this study. The patients did not
receive any cytotoxic/endocrine treatment prior to surgery. The tissue samples were obtained following
surgical interventions at “La Maddalena” Hospital of Palermo and were immediately cryo-preserved
at −80 ◦C until use, as already reported [65–67]. The non-tumoral adjacent tissues were located at
least 5 cm away from the primary tumor. Blood samples were obtained prior to surgery, using plastic
tubes without coagulation accelerators to prevent the release of gelatinases during platelet activation.
The study was carried out after fulfilling all required ethical standards with the informed consent of
patients and with the approval of the Institutional Review Board (N◦515/2008, 13 May 2008) from the
La Maddalena Hospital. Healthy sera (n = 16) were taken from healthy volunteers.
4.2. Tissues and Sera Processing
The frozen tissues were homogenized in an ice bath with 50 mM Tris-HCl pH 7.5, 0.003% penicillin,
0.005% streptomycin and incubated under rotation overnight at 4 ◦C. Tissue lysates were centrifuged
several times at 10,000 rpm for 20 min to remove cell debris. Protein content was quantified by
Bradford assay, as already reported [68,69]. Blood, 30 m after collection, was centrifuged at 1600×
g for 10 min, and sera were aliquoted and used only once to prevent enzymatic activation due to
freeze-thawing processes.
4.3. Western Blotting Analysis
Aliquots containing 20 µg of cell lysates from breast cancer tissues and paired non tumoral
adjacent tissues were subjected to SDS polyacrylamide gel electrophoresis and transferred into a
nitrocellulose membrane (HyBond ECL, Amersham, GE Healthcare Bjorkgatan, Uppsala, Sweden).
Membranes were blocked with 5% milk in T-TBS solution for 1 h at room temperature and then
incubated overnight at 4 ◦C with a mouse monoclonal antibody for ENO1 or Actin β by Santa Cruz
Biotechnology (Santa Cruz, CA, USA). A monoclonal specific antibody to the C-terminus (ENO19/8)
was affinity-purified on ProA-Sepharose 4B, as previously described [24]. Following incubation with
the mouse peroxidase-linked antibody, the reaction was revealed by the ECL detection system, using
high performance films (Hyperfilm ECL, Amersham, GE Healthcare Bjorkgatan, Uppsala, Sweden), as
already described [70–72]. The correct protein loading was ascertained by red Ponceau staining and
immunoblotting for Actin β. Densitometric analysis was performed with ImageJ software to quantify
signals. When the activated forms migrated as multiple bands in consequence of post-translational
modifications, the quantification was performed considering all bands, defining a single region
of interest.
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4.4. Kaplan–Meier Plotter Database Analysis
The KM Plotter database [73] (http://kmplot.com/analysis/), able to assess the effect of 54,675 genes
on survival using 10,461 cancer samples, including 5143 breast, was queried to evaluate the prognostic
values of ENO1, MMP-2 and MMP-9 in breast cancer. The desired probes ID was entered into the
database and patients were split into high and low expression group by the best cut-off values of
mRNA expression. When the best cut-off is selected, all possible cut-off values between the lower and
upper quartiles are computed, and the best performing threshold is used.
4.5. Gelatin Zymography
Gelatin zymography is used to detect gelatinases activity (MMP-2 and MMP-9) after SDS-PAGE
electrophoresis separation. MMP-2 and MMP-9 remain inactive while they are with their pro-domains.
They need proteolytic processing or denaturation to get activated. Denaturation induced by SDS
in SDS-PAGE, activate the enzymes. MMP-2 (72 kDa) and MMP-9 (92 kDa) can be detected on
gelatin zymograms as two-three white bands (pro and active forms) after staining with Coomassie
Blue. Aliquots containing 18 µg of cell lysates from breast cancer tissues and paired non tumoral
adjacent tissues or 10 µl of sera previously diluted 1:25 were separated by electrophoresis on a
7.5% sodium dodecyl sulfate (SDS)–polyacrylamide gel containing 0.1% gelatin, under non-reducing
conditions [4,74]. After electrophoresis, the gels were washed for 1 h with a buffer containing 50 mM
Tris-HCl, pH 7.5 and 2.5% Triton X-100 to remove SDS and then incubated for 18 h at 37 ◦C with
the activation buffer composed of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2. Gels were
stained with Coomassie Brilliant Blue G 250 and de-stained with H2O milliQ. The bands intensity was
measured with ImageJ software.
4.6. Immunohistochemistry
Immunommunohistochemistry was performed on tissue sections from archived formalin-fixed,
paraffin-embedded tissue blocks from patients. Sections of 3 µm were cut, deparaffinized in xylene
and hydrated in a graded series of alcohol. After antigen retrieval in citrate buffer, staining was
performed using the BenchMark automated staining system (Ventana Medical System, Tucson, AZ,
USA) with primary antibodies against ENO1 affinity purified monoclonal antibodies (mAbs) (ENO19/8
1.0 µg/mL). Rabbit anti-human polyclonal antibodies were used as a negative control (dilution 1:500).
ENO1 expression into the cytoplasm and nucleus was empirically determined. In addition, for nuclear
staining, the percentage of cells labeling was graded as negative for ≤20%, or positive for >20%.
4.7. Cell Cultures
MDA-MB-231 cells were cultured in DMEM medium (Gibco, Paisley, UK) supplemented with
10% heat-inactivated fetal bovine serum and 100 U/mL penicillin, 100 µg/mL streptomycin and then
maintained at 37 ◦C and 5% CO2, as already described elsewhere [4,5,75].
4.8. Cell Proliferation Assay
The cell proliferation rate was determined using MTT assay (Promega, Madison, WI, USA). Briefly,
cells were plated at 5 × 103 cells/well in 96-well plates. After adhesion achievement, cells were starved
for 24 h without serum and then treated for 24 h with 1% of FBS or 1% of breast cancer sera of MBP-1-ve
and MBP-1+ve tumors. An amount of 20 µL of the cell titer 96®AQueous reagent was added to each
well after three washes with phosphate buffer saline (PBS) and incubated for 14 h at 37 ◦C in a CO2
incubator. The absorbance was recorded at 490 nm using a 96-well plate reader (Spark® 20M, Tecan
Trading AG, Switzerland). The percentage of cell viability was calculated with respect to untreated
control cells for each treatment after subtraction of the blank.
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4.9. In Vitro Scratch Assay
Scratch assay was performed to analyze cell migration after FBS or breast cancer sera stimulation.
Cells were seeded on 24-well plates and grown to 100% confluence. Wounds were created by scraping
the monolayer of cells with a sterile pipette tip, washed with PBS to remove the floating cells and then
incubated with fresh medium in the presence of 1% of FBS or 1% of breast cancer sera of MBP-1-ve
and MBP-1+ve tumors. The images of scratched area were captured (at 40× magnification) using an
inverted microscope equipped with digital camera immediately after wounding and after 6 and 24 h.
The scratched area was calculated by ImageJ software.
4.10. Statistical Analysis
All data were analyzed by using GraphPad Prism version 5.0 for Windows (GraphPad Software,
Inc. La Jolla, CA, USA) and presented as means ± standard deviation of at least three experiments.
The statistical significance of differences was assessed by Mann Whitney or the Kruskal–Wallis test.
* p < 0.05 was considered significant; ** p< 0.01 highly significant and *** p < 0.001 very highly
significant. The data in the graphs are expressed as median ± SD.
5. Conclusions
Our data, in addition to previous evidence allow a better breast patients stratification based on
homogeneous prognosis, in fact while the high expression of ENO1 and MMPs are associated with
a worse prognosis, the expression of MBP-1 is associated with a decrease in MMPs activity, a less
aggressive biological features of the tumor and better prognosis.
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